Literature DB >> 29338289

A systematic review of risk factors for methamphetamine-associated psychosis.

Shalini Arunogiri1,2, James A Foulds3, Rebecca McKetin4, Dan I Lubman1,2.   

Abstract

OBJECTIVE: Chronic methamphetamine use is commonly associated with the development of psychotic symptoms. The predictors and correlates of methamphetamine-associated psychosis are poorly understood. We sought to systematically review factors associated with psychotic symptoms in adults using illicit amphetamine or methamphetamine.
METHODS: A systematic literature search was performed on MEDLINE (OVID), PsycINFO and EMBASE databases from inception to 8 December 2016. The search strategy combined three concept areas: methamphetamine or amphetamine, psychosis and risk factors. Included studies needed to compare adults using illicit methamphetamine or amphetamine, using a validated measure of psychosis, on a range of risk factors. Of 402 identified articles, we removed 45 duplicates, 320 articles based on abstract/title and 17 ineligible full-text articles, leaving 20 included studies that were conducted in 13 populations. Two co-authors independently extracted the following data from each study: country, setting and design; participant demographic and clinical details; sample size; measure/s used and measures of association between psychosis outcomes and risk factors. Individual study quality was assessed using a modified Newcastle-Ottawa Scale, and strength of evidence was assessed using GRADE criteria.
RESULTS: Frequency of methamphetamine use and severity of methamphetamine dependence were consistently found to be associated with psychosis, and sociodemographic factors were not. There was inconsistent evidence available for all other risk factors. Individual study quality was low-moderate for the majority of studies. Heterogeneity in study outcomes precluded quantitative synthesis of outcomes across studies.
CONCLUSION: The most consistent correlates of psychotic symptoms were increased frequency of methamphetamine use and dependence on methamphetamine. The findings of this review highlight the need for targeted assessment and treatment of methamphetamine use in individuals presenting with psychosis.

Entities:  

Keywords:  Methamphetamine; dual diagnosis; psychosis; risk factor; substance-induced psychosis

Mesh:

Substances:

Year:  2018        PMID: 29338289     DOI: 10.1177/0004867417748750

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  18 in total

1.  Sleep Deprivation & Amphetamine Induced Psychosis.

Authors:  Amr Said Shalaby; Abdullah Osama Bahanan; Mishal Hasan Alshehri; Khaled Ahmed Elag
Journal:  Psychopharmacol Bull       Date:  2022-06-27

Review 2.  A review of basic to clinical studies of the association between hyperammonemia, methamphetamine.

Authors:  Marzieh Jafari Fakharbad; Mohammad Moshiri; Mohammad Mehdi Ommati; Mehdi Talebi; Leila Etemad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-23       Impact factor: 3.195

3.  Characterising methamphetamine use to inform health and social policies in Manitoba, Canada: a protocol for a retrospective cohort study using linked administrative data.

Authors:  Nathan C Nickel; Jennifer E Enns; Amy Freier; Scott C McCulloch; Mariette Chartier; Hera J M Casidsid; Oludolapo Deborah Balogun; Drew Mulhall; Roxana Dragan; Joykrishna Sarkar; James Bolton; Geoffrey Konrad; Wanda Phillips-Beck; Julianne Sanguins; Carolyn Shimmin; Neil McDonald; Javier Mignone; Aynslie Hinds
Journal:  BMJ Open       Date:  2022-10-19       Impact factor: 3.006

4.  Latent Psychotic Symptom Profiles Amongst People Who Use Methamphetamine: What Do They Tell Us About Existing Diagnostic Categories?

Authors:  Rebecca McKetin; Alexandra Voce; Richard Burns; Robert Ali; Dan I Lubman; Amanda L Baker; David J Castle
Journal:  Front Psychiatry       Date:  2018-11-19       Impact factor: 4.157

Review 5.  A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms.

Authors:  Xiangwen Chang; Yan Sun; Yang Zhang; Jiana Muhai; Lin Lu; Jie Shi
Journal:  Front Psychiatry       Date:  2018-11-16       Impact factor: 4.157

6.  Testing a hypothesis arising from the epidemiology of schizophrenia in New Zealand.

Authors:  Graham Mellsop; Rees Tapsell; David Benjamin Menkes
Journal:  Gen Psychiatr       Date:  2019-04-14

Review 7.  Responding to global stimulant use: challenges and opportunities.

Authors:  Michael Farrell; Natasha K Martin; Emily Stockings; Annick Bórquez; Javier A Cepeda; Louisa Degenhardt; Robert Ali; Lucy Thi Tran; Jürgen Rehm; Marta Torrens; Steve Shoptaw; Rebecca McKetin
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

8.  Epidemiological Characteristics and Risk Factors of Methamphetamine-Associated Psychotic Symptoms.

Authors:  Meng-Fan Su; Mo-Xuan Liu; Jin-Qiao Li; Julia M Lappin; Su-Xia Li; Ping Wu; Zhi-Min Liu; Jie Shi; Lin Lu; Yanping Bao
Journal:  Front Psychiatry       Date:  2018-10-12       Impact factor: 4.157

Review 9.  A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.

Authors:  Travis A Wearne; Jennifer L Cornish
Journal:  Front Psychiatry       Date:  2018-10-10       Impact factor: 4.157

10.  A Research of Methamphetamine Induced Psychosis in 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features and Possible Risk Factors.

Authors:  Hong Gan; Yan Zhao; Haifeng Jiang; Youwei Zhu; Tianzhen Chen; Haoye Tan; Na Zhong; Jiang Du; Min Zhao
Journal:  Front Psychiatry       Date:  2018-11-06       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.